摘要
After an initial phase of skepticism and technical difficulties,minimally invasive liver surgery(MILS)has become a widespread practice in most high-volume hepatobiliary centers.Since the first laparoscopic liver resection(LLR)was carried out in France in 1991 for a benign lesion,the indications have substantially changed,including malignant diseases such as hepatocellular carcinoma(HCC)[1].Thanks to the improvements in both technical aspects and perioperative management,the extent of resection has also expanded during the last years,including patients with more advanced disease[2].With this redefinition of the boundaries of MILS,liver surgeons must be aware of the specific issues concerning HCC treatment,as well as the current evidence and strategies to overcome old limits.
